This Article Figures Only Full Text Full Text (PDF) Online Appendix View Related Cardiosource Journal Scan Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Alfonso, F. PubMed Articles by Alfonso, F. Related Collections Related Article

CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY

Long-Term Clinical Benefit of Sirolimus-Eluting Stents in Patients With In-Stent Restenosis

Results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) Study

Fernando Alfonso, MD^_*,_*, María-José Pérez-Vizcayno, MD^_*, Rosana Hernández, MD^_*, Armando Bethencourt, MD, Vicens Martí, MD, José R. López-Mínguez, MD, Juan Angel, MD^||, Andrés Iñiguez, MD^¶, César Morís, MD^#, Angel Cequier, MD^_**, Manel Sabaté, MD, Javier Escaned, MD^_*, Pilar Jiménez-Quevedo, MD^_*, Camino Bañuelos, MD^_*, Alfonso Suárez, MD^_*, Carlos Macaya, MD^_* for the RIBS-II Investigators

^_* University Hospital, Clinico San Carlos, Madrid, Spain
University Hospital, Son Dureta, Palma de Mallorca, Spain
University Hospital, San Pablo, Barcelona, Spain
University Hospital, Infanta Cristina, Badajoz, Spain
^|| University Hospital, Valle de Hebrón, Barcelona, Spain
^¶ University Hospital, Meixoeiro, Vigo, Spain
^# University Hospital, Central Asturias, Oviedo, Spain
^_** University Hospital, Bellvitge, Barcelona, Spain

Manuscript received June 12, 2008; revised manuscript received August 11, 2008, accepted August 19, 2008.

^_* Reprint requests and correspondence: Dr. Fernando Alfonso, Cardiología Intervencionista, Instituto Cardiovascular, Hospital Universitario "San Carlos," Ciudad Universitaria, Plaza de Cristo Rey, Madrid 28040 Spain (Email: falf{at}hotmail.com).

Objectives: We sought to assess the long-term effectiveness and safety of sirolimus-eluting stents (SES) in patients with in-stent restenosis (ISR).

Background: Treatment of patients with ISR remains a challenge. The long-term outcome of patients with ISR treated with SES remains unknown.

Methods: The RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study was a randomized trial conducted in 150 patients with ISR (76 SES, 74 balloon angioplasty [BA]). The long-term (>1 year) clinical outcome and pre-specified subgroup analyses were pre-defined secondary study end points.

Results: At 1 year, the event-free survival (death, myocardial infarction, target vessel revascularization [TVR]) was better in the SES group (88% vs. 69%, p < 0.005). Additional long-term (>3 years) clinical follow-up was obtained in 97% of patients (median 3.3 years). After the first year, 3 patients died (1 SES, 2 BA), 5 suffered myocardial infarction (4 SES, 1 BA), and 7 required TVR (4 SES, 3 BA). At last follow-up, definitive/probable/possible stent thrombosis was similar in both groups (2/2/1 SES vs. 1/0/3 BA, p = NS). At 4 years, the event-free survival was 76% in the SES arm and 65% in the BA arm (p = 0.019). On multivariate analysis, SES implantation was an independent predictor of event-free survival. Subgroup analyses were consistent with the main outcome measure.

Conclusions: In patients with ISR, SES implantation remains effective and safe at very long-term clinical follow-up.

Key Words: angiography • angioplasty • restenosis • sirolimus-eluting stents

Abbreviations and Acronyms   BA = balloon angioplasty   CI = confidence interval   DES = drug-eluting stent(s)   HR = hazard ratio   ISR = in-stent restenosis   MI = myocardial infarction   SES = sirolimus-eluting stent(s)   TVR = target vessel revascularization

Related Article

Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 52: A28. [Full Text] [PDF]